Mohamed Awad E. Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Awad E. Ahmed has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Khalid Radwan Alsaadany
Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications - Mohamed Ezzat M. Mansour
Faculty of Medicine, Zagazig University, Zagazig, Egypt
3 shared publications - Mufreh Amin
Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt
3 shared publications - Omar Kassar
Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 shared publications - Yomna Emad Abdalla
Faculty of Medicine, Zagazig University, Zagazig City, Egypt
2 shared publications - Ahmed Ezzat Elmetwalli
Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Efficacy and safety of theta-burst stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis
- 18 August 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessEfficacy and safety of theta-burst stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis
- Open Access
- 11 May 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 384
N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials
Introduction: Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are thought to be significant global contributors to the burden of mental illness. According to recent WHO epidemiological estimates, 3.9% of people worldwide have experienced PTSD at some point in their lives; this number rises to roughly 5.6% among those who have experienced trauma. NAC has shown promise in reducing PTSD symptoms and cravings in veterans, according to recent trials. Our analysis aims to resolve the conflict between results and determine whether NAC is an effective add-on therapy for PTSD, AUD, and co-occurring PTSD/AUD. Methods: We conducted this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD420251170956). We searched PubMed, Scopus, Cochrane CENTRAL, Embase, EBSCO, and the Web of Science for relevant studies. Only randomized placebo-controlled trials were included. The primary outcomes were severity of PTSD and alcohol craving, while secondary outcomes were anxiety, depression, and alcohol use patterns and biomarkers. Results: Seven randomized, double-blind, placebo-controlled trials were included in this meta-analysis, enrolling a total of 566 participants. There were no significant differences between NAC and placebo in craving (SMD= -0.40, 95% CI [-1.05, 0.25], P = 0.22, I² = 56.1%). Regarding PTSD severity, the PCL scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = 0.04, 95% CI [-0.40, 0.48], P = 0.8) (I² = 65.9%, P = 0.05), while the CAPS scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = -0.13, 95% CI [-0.50, 0.24], P = 0.49) (I² = 54.8%, P = 0.109). Leave-one-out sensitivity analysis showed that exclusion of the Back et al. (2025) study resulted in a significant effect favoring NAC (SMD = -0.35, 95% CI [-0.70, -0.01], P = 0.04), with no observed heterogeneity (I² = 0%). Conclusion: Our meta-analysis indicates that N-acetylcysteine, when compared to placebo, does not demonstrate consistent efficacy in reducing the primary symptoms of AUD or PTSD in broad patient populations. However, the treatment is relatively safe. A noteworthy signal of potential efficacy for PTSD symptoms emerged in a sensitivity analysis, suggesting that the therapeutic promise of NAC should not be entirely dismissed. Clinical trial number: Not applicable.
- 11 May 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1) , 384
Open AccessN-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials
Introduction: Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are thought to be significant global contributors to the burden of mental illness. According to recent WHO epidemiological estimates, 3.9% of people worldwide have experienced PTSD at some point in their lives; this number rises to roughly 5.6% among those who have experienced trauma. NAC has shown promise in reducing PTSD symptoms and cravings in veterans, according to recent trials. Our analysis aims to resolve the conflict between results and determine whether NAC is an effective add-on therapy for PTSD, AUD, and co-occurring PTSD/AUD. Methods: We conducted this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, following our protocol (CRD420251170956). We searched PubMed, Scopus, Cochrane CENTRAL, Embase, EBSCO, and the Web of Science for relevant studies. Only randomized placebo-controlled trials were included. The primary outcomes were severity of PTSD and alcohol craving, while secondary outcomes were anxiety, depression, and alcohol use patterns and biomarkers. Results: Seven randomized, double-blind, placebo-controlled trials were included in this meta-analysis, enrolling a total of 566 participants. There were no significant differences between NAC and placebo in craving (SMD= -0.40, 95% CI [-1.05, 0.25], P = 0.22, I² = 56.1%). Regarding PTSD severity, the PCL scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = 0.04, 95% CI [-0.40, 0.48], P = 0.8) (I² = 65.9%, P = 0.05), while the CAPS scale pooled analysis demonstrated no significant difference between NAC and placebo (SMD = -0.13, 95% CI [-0.50, 0.24], P = 0.49) (I² = 54.8%, P = 0.109). Leave-one-out sensitivity analysis showed that exclusion of the Back et al. (2025) study resulted in a significant effect favoring NAC (SMD = -0.35, 95% CI [-0.70, -0.01], P = 0.04), with no observed heterogeneity (I² = 0%). Conclusion: Our meta-analysis indicates that N-acetylcysteine, when compared to placebo, does not demonstrate consistent efficacy in reducing the primary symptoms of AUD or PTSD in broad patient populations. However, the treatment is relatively safe. A noteworthy signal of potential efficacy for PTSD symptoms emerged in a sensitivity analysis, suggesting that the therapeutic promise of NAC should not be entirely dismissed. Clinical trial number: Not applicable.
- 9 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106980
Exposure to tobacco smoke during pregnancy and the risk of multiple sclerosis in offspring: A systematic review and meta-analysis
- 9 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106980
Exposure to tobacco smoke during pregnancy and the risk of multiple sclerosis in offspring: A systematic review and meta-analysis